Anavex life sciences to present at the h.c. wainwright 5th annual neuro perspectives virtual conference

New york, june 20, 2024 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders including alzheimer's disease, parkinson's disease, rett syndrome, schizophrenia, and other central nervous system (cns) diseases, today announced that christopher u. missling, phd, president and chief executive officer of anavex, will present at the h.c. wainwright 5th annual neuro perspectives virtual conference being held june 27, 2024.
AVXL Ratings Summary
AVXL Quant Ranking